SANA BIOTECHNO. DL -,0001

Sana Biotechnology said at the Citigroup Biopharma Summit that its type 1 diabetes program SC451 is close to filing an IND and proof‑of‑concept data could be expected about one month after the first patient dose. The in‑vivo CAR‑T program SG293 remains active, but initial data in China are delayed to the first half of 2027 due to regulatory setbacks. Sana has roughly $160 million in cash, sees no urgent near‑term funding need, and plans to tie future capital raises to clinical milestones. » Más en de.investing.com

Sana Biotechnology confirmed that an abstract with preclinical data on its in‑vivo CAR‑T product candidate SG293 was accepted for an oral presentation at the ASGCT annual meeting on May 12, 2026. SG293 uses fusogen‑based delivery and specifically targets CD8+ T cells to generate CD19‑directed CAR‑T cells, while aiming to avoid delivery to other tissues such as the liver. The company plans to further investigate SG293 in B‑cell cancers and B‑cell‑mediated autoimmune diseases. » Más en de.investing.com

Sana Biotechnology reports 14‑month follow‑up data from a first‑in‑human study in which a type 1 diabetes patient received HIP‑modified allogeneic islet cells (UP421) transplanted without immunosuppression. C‑peptide levels indicate sustained survival and functional insulin responses after meals; no safety issues were reported and a PET‑MRI at 52 weeks localized islet cells at the transplant site. The company recorded negative free cash flow of USD 145 million over the past twelve months, its stock trades well below analyst targets, and Sana plans to file an IND this year for the stem‑cell therapy SC451. » Más en de.investing.com